Myo9b is required for T cell accumulation in NLTs. (A) Experimental layout of HSV-1_TOM-OVA skin infection. (B) Percentage of WT and Myo9b^−/− OT-I T cells in blood on days 8, 14, and 30 after infection. (C) Percentage of WT and OT-I Myo9b^−/− T cells (FSC/SSC/singlet gate) in spleen, PLN, MLN, SMG, and skin of HSV-1_TOM-OVA–infected mice on day 30 after infection. Each dot represents data from one mouse in two independent experiments. (D) WT and Myo9b^−/− OT-I T cells (brown) in epidermis (blue circles) and dermis (yellow circles) on day 30 after infection IHCS were counterstained with Mayer’s Hematoxylin. Nuclei are in blue. Bars, 50 µm. (E) Quantification of WT and Myo9b^−/− OT-I T cell distribution per cm² of epidermis (Epi) or dermis (D). Each dot represents one skin section pooled from two independent experiments with three mice and six sections analyzed per genotype. (F) Flow cytometry of activation parameters of WT and Myo9b^−/− OT-I T cells on day 30 after infection in PLN and skin. Filled-color histograms are isotype controls. (G) Flow cytometry of activation parameters of WT and Myo9b^−/− OT-I T cells on day 30 after infection in skin. Filled-color histograms are FMO controls. Statistical analysis: unpaired Student’s t test (B and C); ANOVA between selected columns with Sidak’s multiple comparison test. ***, P < 0.001. Horizontal bars depict mean.